drugset / Trial / NCT00665106

Safety and Tolerability of NOVA63035 "Corticosteroid" in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

NCT00665106

Phase 1 Completed 20 enrolled Santen SAS
Non-randomizedSingle-groupOpen-labelSupportive care

Summary

Evaluation of safety and tolerability of a single injection of NOVA63035 "Corticosteroid" administered at one of four doses in patients with diabetic macular edema (DME) secondary to diabetic retinopathy

Timeline

Start
2008-04
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Palmitate Other / unclassified 0.8 %
Subject Dexamethasone Palmitate Other / unclassified 3.2 %
Subject Dexamethasone Palmitate Other / unclassified 3.4 %